Natassja G Bush, Isabel Diez-Santos, Pilla Sankara Krishna, Bernardo Clavijo, Anthony Maxwell
{"title":"Insights into antibiotic resistance promoted by quinolone exposure.","authors":"Natassja G Bush, Isabel Diez-Santos, Pilla Sankara Krishna, Bernardo Clavijo, Anthony Maxwell","doi":"10.1128/aac.00997-24","DOIUrl":null,"url":null,"abstract":"<p><p>Quinolone-induced antibiotic resistance (QIAR) refers to the phenomenon by which bacteria exposed to sublethal levels of quinolones acquire resistance to non-quinolone antibiotics. We have explored this in <i>Escherichia coli</i> MG1655 using a variety of compounds and bacteria carrying a quinolone-resistance mutation in gyrase, mutations affecting the SOS response, and mutations in error-prone polymerases. The nature of the antibiotic-resistance mutations was determined by whole-genome sequencing. Exposure to low levels of most quinolones tested led to mutations conferring resistance to chloramphenicol, ampicillin, kanamycin, and tetracycline. The mutations included point mutations and deletions and could mostly be correlated with the resistance phenotype. QIAR depended upon DNA gyrase and involved the SOS response but was not dependent on error-prone polymerases. Only moxifloxacin, among the quinolones tested, did not display a significant QIAR effect. We speculate that the lack of QIAR with moxifloxacin may be attributable to it acting via a different mechanism. In addition to the concerns about antimicrobial resistance to quinolones and other compounds, QIAR presents an additional challenge in relation to the usage of quinolone antibacterials.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0099724"},"PeriodicalIF":4.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.00997-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Quinolone-induced antibiotic resistance (QIAR) refers to the phenomenon by which bacteria exposed to sublethal levels of quinolones acquire resistance to non-quinolone antibiotics. We have explored this in Escherichia coli MG1655 using a variety of compounds and bacteria carrying a quinolone-resistance mutation in gyrase, mutations affecting the SOS response, and mutations in error-prone polymerases. The nature of the antibiotic-resistance mutations was determined by whole-genome sequencing. Exposure to low levels of most quinolones tested led to mutations conferring resistance to chloramphenicol, ampicillin, kanamycin, and tetracycline. The mutations included point mutations and deletions and could mostly be correlated with the resistance phenotype. QIAR depended upon DNA gyrase and involved the SOS response but was not dependent on error-prone polymerases. Only moxifloxacin, among the quinolones tested, did not display a significant QIAR effect. We speculate that the lack of QIAR with moxifloxacin may be attributable to it acting via a different mechanism. In addition to the concerns about antimicrobial resistance to quinolones and other compounds, QIAR presents an additional challenge in relation to the usage of quinolone antibacterials.
喹诺酮诱导的抗生素耐药性(QIAR)是指细菌暴露于亚致死水平的喹诺酮类药物后对非喹诺酮类抗生素产生耐药性的现象。我们在大肠杆菌 MG1655 中使用多种化合物和携带喹诺酮抗性回旋酶突变、影响 SOS 反应的突变和易错聚合酶突变的细菌进行了探索。抗生素耐药性突变的性质是通过全基因组测序确定的。接触低浓度的大多数喹诺酮类药物会导致对氯霉素、氨苄西林、卡那霉素和四环素产生抗药性突变。这些突变包括点突变和缺失,大多与耐药性表型相关。QIAR 依赖于 DNA 回旋酶并涉及 SOS 反应,但不依赖于易出错的聚合酶。在测试的喹诺酮类药物中,只有莫西沙星没有显示出明显的 QIAR 效果。我们推测,莫西沙星不产生 QIAR 的原因可能是它通过不同的机制发挥作用。除了对喹诺酮类和其他化合物的抗菌药耐药性的担忧外,QIAR 还对喹诺酮类抗菌药的使用提出了额外的挑战。
期刊介绍:
Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.